Actively Recruiting
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
Led by Anhui Provincial Hospital · Updated on 2024-06-04
60
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
CONDITIONS
Official Title
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients are receiving a first unrelated cord blood transplantation (UCBT).
- Patients start letermovir prophylaxis within 0-28 days post UCBT.
You will not qualify if you...
- Patients having active CMV DNAemia at the time of letermovir initiation.
- Patients recruited in a clinical study on an anti-CMV trial.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provincial Hospital
Hefei, Anhui, China
Actively Recruiting
Research Team
X
Xiaoyu Zhu, ph.D
CONTACT
B
Bingbing Yan
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here